Can-Fite Completes Patient Enrollment for Interim Analysis of Pivotal Phase 3 Psoriasis Study

Can-Fite BioPharma Ltd. has completed the enrollment of the first 247 patients in its pivotal Phase 3 study evaluating Piclidenoson for the treatment of moderate-to-severe plaque psoriasis. This milestone triggers the pre-specified interim analysis, which will assess the efficacy and safety data under a protocol agreed upon with both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Results from this interim analysis are anticipated in Q4 2026 or Q1 2027.

Context

Can-Fite BioPharma Ltd. is conducting a pivotal Phase 3 study to evaluate Piclidenoson, a drug aimed at treating moderate-to-severe plaque psoriasis. The study involves collaboration with regulatory authorities, including the FDA and EMA, ensuring that the research adheres to established safety and efficacy standards. Psoriasis is a prevalent condition that can significantly impact quality of life.

Why it matters

The completion of patient enrollment is a significant step in the development of new treatments for psoriasis, a chronic skin condition affecting millions. The interim analysis will provide critical insights into the efficacy and safety of Piclidenoson, potentially influencing treatment options for patients. Positive results could lead to regulatory approvals and wider availability of this therapy.

Implications

If the interim analysis shows positive results, it could pave the way for regulatory approval of Piclidenoson, benefiting patients with limited treatment options. Healthcare providers may gain a new therapeutic tool for managing psoriasis, potentially improving patient outcomes. Conversely, negative results could hinder the drug's development and impact Can-Fite's market position.

What to watch

Results from the interim analysis are expected in late 2026 or early 2027, marking a crucial moment for Can-Fite and the psoriasis treatment landscape. Stakeholders will be closely monitoring the findings for indications of the drug's effectiveness. The response from regulatory bodies following the analysis will also be pivotal in determining the next steps for the drug's development.